Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

The LSEG U.S. Retail and Restaurant Q4 earnings index, which tracks changes in the growth rate of earnings within the sector, ...

NOG shares are trading higher premarket after providing a Q4 operational update and 2025 guidance. Expect 130-135 MBoe/day ...

Enbridge reaffirmed 2024 full year financial guidance and said it continues to enjoy strong capacity utilization and ...

Full Year 2024 Non-GAAP EPS: $13.10. Full Year 2024 Free Cash Flow: $2.3 billion, up 14%. Q4 2024 Revenue: $5.5 billion, up 4% organically. Q4 2024 Segment Operating Margin: 15.3%. Q4 2024 Non ...

Total Revenue (Q4 2024): $179 million, up 6% year-over-year. Gross Profit (Q4 2024): $97.5 million, with a 54% gross margin. Net Income (Q4 2024): $13.3 million, representing 7.4% of revenue. Adjusted ...

Revenue: $530 million for Q4 2024, down 1% year-over-year, flat organically. GAAP Operating Margin: Negative 6.9% due to $93 million in noncash goodwill and intangible impairment charges.

Earnings Per Share (EPS): $1.22 for Q4 2024; $8.46 for the full year 2024. EBITDA: $751 million for Q4 2024; nearly $4.4 billion for the full year 2024. Net Earnings: $287 million for Q4 2024; ...

New Accounts Added: 5 million in Q4 2024; 20 million for the full year 2024. Purchase Volume: $48 billion in Q4 2024; over $182 billion for the full year 2024. Ending Loan Receivables Growth: 2% ...

Even while net revenue was impacted by the exit of unprofitable partnerships, gross margin1 improved 10.0%, 30.4% and 12.0% in Q2, Q3 and Q4 of fiscal 2024, respectively. Additionally, due to ...

2024 Q4 revenue in Benelux stood at €92.7 million, down -17.2% (-17.6% organically) from a particularly high comparison basis (+61% in Q4 of 2023). Connectivity activities posted revenue of €67.3 ...